Department of Dermatology, Le Mans Hospital, Le Mans, France.
Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Tours, France.
Dermatol Ther. 2022 Aug;35(8):e15620. doi: 10.1111/dth.15620. Epub 2022 Jun 16.
Primary focal hyperhidrosis (PFH) is a frequent condition which can seriously affect the quality of life. Intradermal injections of botulinum toxin A (BTA) is a safe temporary treatment. The objective was to assess the factors associated with the efficacy of the axillary injections of abobotulinumtoxinA in PFH. Among a cohort of 236 patients followed for axillary injections of BTA between 2001 and 2020 for severe PFH, we included patients treated with 150 units per armpit of abobotulinumtoxinA with a minimum follow-up of three years. We described the characteristics of the patients and then searched for association between variables (sex, age, multifocal PFH and duration of efficacy of the first injection [<6 or ≥6 months]) and the number of injections received in three years, counted at the second injection date, by univariate and multivariate logistic regression. Ninety patients were included (62 women, median age of 29 years and 12.2% of multifocal PFH). The median duration of efficacy of the first injection was six months (interquartile range 3-9). The duration of efficacy of the first injection ≥6 months was significantly associated with less injections during the 3-year follow-up in univariate (odds ratio [OR]: -1.18 [95% confidence interval (CI): -1.80 to -0.55]; p < 0.01) and multivariate (OR: -1.16 [95% CI: -1.79 to -0.53]; p < 0.01) logistic regression. There was no significant difference with female sex, age, or multifocal PFH. A duration of efficacy of the first injection greater than six months seems to indicate a better response profile to BTA.
原发性局限性多汗症（PFH）是一种常见病症，可严重影响生活质量。肉毒毒素 A（BTA）皮内注射是一种安全的临时治疗方法。本研究旨在评估与 PFH 腋窝注射 abobotulinumtoxinA 疗效相关的因素。在 2001 年至 2020 年间因严重 PFH 接受腋窝 BTA 注射治疗的 236 例患者队列中，我们纳入了接受 150 单位/腋窝 abobotulinumtoxinA 治疗且至少随访 3 年的患者。我们描述了患者的特征，然后通过单变量和多变量逻辑回归，寻找变量（性别、年龄、多灶性 PFH 和第一次注射疗效持续时间[＜6 个月或≥6 个月]）与三年内接受的注射次数之间的关联，以第二次注射日期为计数日期。90 例患者入选（62 例女性，中位年龄 29 岁，12.2%为多灶性 PFH）。第一次注射疗效的中位持续时间为 6 个月（四分位距 3-9）。第一次注射疗效持续时间≥6 个月与单变量（比值比[OR]：-1.18[95%置信区间（CI）：-1.80 至-0.55]；p<0.01）和多变量（OR：-1.16[95%CI：-1.79 至-0.53]；p<0.01）逻辑回归中，3 年随访期间的注射次数减少显著相关。性别、年龄或多灶性 PFH 与疗效无显著差异。第一次注射疗效持续时间大于 6 个月似乎表明对 BTA 的反应更好。
